![](https://investorshub.advfn.com/uicon/335383.png?cb=1609924894)
Monday, June 29, 2015 1:57:06 PM
Tonix Pharma (TNXP) Fair Value Raised to $12 at Janney Capital
June 29, 2015 6:55 AM
Janney Capital analyst Chiara Russo reiterated a Buy rating and adjusted its fair value target on Tonix Pharma (NASDAQ: TNXP) to $12.00 (from $10.00), saying non-clinical study supports TNX-201 in headache.
Russon commented, "We spent some time with Tonix CEO Seth Lederman this week following their poster presentations at the Annual Scientific Meeting of the American Headache Society. Though non-clinical in nature, one poster in particular caught our eye as it supports the development of TNX-201 in tension headache as the isolated (R)-isomer of isometheptene decreased trigeminal (cranial nerve) pain in not one, but two established rat models."
I bought back in at 8.80
GLTA
Recent TNXP News
- Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024 • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:05:23 PM
- Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:24:27 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/13/2024 09:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:01:03 PM
- Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/11/2024 09:17:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/11/2024 08:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:53:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:21:23 PM
- Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:05:39 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:05:27 PM
- Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 12:05:48 PM
- Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:10:58 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM